The Science of Psychedelics

How Psychedelics Work

Classical serotonergic psychedelics — psilocybin, LSD, DMT, mescaline, and related compounds — produce their primary psychoactive effects through agonism at serotonin 5-HT_2A receptors, which are densely expressed in cortical regions associated with perception, cognition, and self-referential processing. Blockade of 5-HT_2A receptors by drugs such as ketanserin substantially abolishes the psychedelic state, confirming this receptor's central role.

The most influential framework for understanding what 5-HT_2A activation actually does is the REBUS model (Relaxed Beliefs Under Psychedelics), developed by Carhart-Harris and Friston (2019). Under ordinary conditions, the brain operates as a predictive system: strong top-down priors constrain what it registers, effectively suppressing sensory noise and stabilising perception and self-concept. Psychedelics flatten this hierarchy — reducing the dominance of top-down priors and increasing the relative weight of bottom-up sensory information. The result is a more fluid, open, and contextually sensitive mode of processing.

Beyond 5-HT_2A, recent research has identified additional mechanisms of significant therapeutic interest. Casarotto and colleagues (2021) demonstrated in Cell that antidepressants and psychedelics — including psilocin and LSD — directly bind TrkB, the primary receptor for brain-derived neurotrophic factor (BDNF), with high affinity. This TrkB binding promotes neuroplasticity independently of 5-HT_2A agonism, and may help explain why therapeutic effects often persist well beyond the acute experience. DMT and 5-MeO-DMT additionally act at sigma-1 receptors, which are involved in neuroprotection and cellular stress responses. These multi-target profiles suggest that psychedelic pharmacology is considerably more complex than early serotonergic models implied.

Effects on the Brain

Neuroimaging and electrophysiological studies have identified several consistent patterns of acute brain change under psychedelics:

• Disruption of the Default Mode Network (DMN). The DMN — associated with self-referential thought, mind-wandering, and rumination — shows decreased internal coherence and increased communication with networks it does not ordinarily interact with, including sensory and attentional systems. This disruption correlates with ego dissolution and may underlie therapeutic value in conditions driven by entrenched negative self-referential patterns such as depression and OCD.
• Increased neural entropy and global connectivity. Psychedelics produce a state of higher neural complexity — more varied, less predictable activity — alongside increased long-range communication between brain regions. This represents a shift away from the brain's ordinary segregated, modular organisation toward a more globally integrated state. Timmermann and colleagues (2023) found that 5-MeO-DMT produced the most globally interconnected brain state yet recorded in humans.
• Increased neuroplasticity. Animal studies show robust promotion of dendritic spine growth and synaptogenesis. Shao and colleagues (2021) demonstrated that psilocybin rapidly increased dendritic spine density in the mouse prefrontal cortex, and these structural changes persisted for at least one month following a single dose. The direct TrkB-binding mechanism identified by Casarotto et al. provides a plausible molecular pathway linking the acute experience to lasting structural change.
• Acute vs. sustained effects. A critical insight from the neuroimaging literature is the dissociation between acute brain states and lasting therapeutic outcomes. The subjective experience typically resolves within hours, yet therapeutic benefits — mood improvement, reduced craving, altered self-concept — are often still present weeks or months later. This temporal dissociation suggests that the acute state catalyses, but is not identical to, the therapeutic process.

Research Landscape

After decades of research moratorium following prohibition in the late 1960s, psychedelic science has undergone a significant revival since the early 2000s, accelerating dramatically from 2016 onwards. Institutions including Johns Hopkins, Imperial College London, NYU, UCSF, and the University of Zurich have published dozens of clinical trials on psilocybin, MDMA, ketamine, LSD, and ibogaine for a range of psychiatric conditions. As of 2025, over 100 registered clinical trials are active globally.

The dominant model is psychedelic-assisted therapy (PAT) — typically one to three carefully prepared dosing sessions embedded within a course of structured psychotherapy. This model reflects the emerging consensus that the compound and the therapeutic container are jointly necessary: neither alone replicates the outcomes produced by both together. Preparation, in-session support, and post-session integration are treated as essential components, not accessories.

Depression

Depression is the most extensively studied indication for psilocybin-assisted therapy. Several landmark trials have produced significant results:

• Davis et al. (2021) published the first RCT of psilocybin for major depressive disorder, finding large effect sizes (Cohen's d > 2.0) for depression and anxiety symptoms, with 71% of participants showing significant response at 4-week follow-up.
• Carhart-Harris et al. (2021) — the Imperial College London trial comparing psilocybin to escitalopram (a standard SSRI) in treatment-resistant depression — found psilocybin comparable to escitalopram on the primary outcome measure at 6 weeks, with advantages on several secondary measures including emotional blunting, which was absent in the psilocybin group.
• COMPASS Pathways Phase 2b (2022) — the largest psilocybin RCT to date, involving 233 participants across 10 countries — found a significant dose-dependent antidepressant effect at 3 weeks for the 25mg dose. However, effect sizes were more modest than earlier open-label studies, reinforcing the importance of expectancy and therapeutic support in outcomes.

MDMA-assisted therapy has also shown antidepressant effects, likely through its distinct mechanism of serotonin, dopamine, and noradrenaline release. Ketamine and its S-enantiomer esketamine (FDA-approved as Spravato since 2019) produce rapid antidepressant effects, typically within hours, in treatment-resistant populations — though effects are often short-lived without repeated dosing.

PTSD and Trauma

MDMA-assisted therapy (MDMA-AT) for post-traumatic stress disorder represents the most clinically advanced application in psychedelic medicine, having completed Phase 3 trials in the United States. MDMA's mechanism — releasing serotonin, dopamine, and noradrenaline while reducing amygdala reactivity to threatening stimuli — appears to create a therapeutic window in which traumatic memories can be processed with reduced fear response and without suppression of emotional access.

Mitchell and colleagues (2021) published the first Phase 3 MDMA-AT trial in Nature Medicine, finding 67% of participants no longer met criteria for PTSD diagnosis at 18-week follow-up, compared to 32% in the placebo-plus-therapy group. A second Phase 3 trial (Mitchell et al., 2023) confirmed these results. Despite these findings, the FDA declined to approve MDMA-AT in 2024, citing concerns about the trial methodology — particularly the blinding challenge — and requesting an additional trial.

Psilocybin is also being investigated for PTSD, with Phase 2 trials underway, though this application is less advanced than the MDMA programme. Ketamine is currently used off-label and in some clinical settings for PTSD, with emerging evidence of benefit particularly in acute stress responses.

Addiction and Substance Use

Some of the most compelling early evidence for psychedelic therapy concerns addiction — an area where current pharmacological treatments remain substantially inadequate for many patients.

• Tobacco cessation. Johnson and colleagues at Johns Hopkins conducted the first modern trial of psilocybin for nicotine dependence (2014), finding 80% abstinence at 6-month follow-up — substantially higher than any existing pharmacological or behavioural intervention. A follow-up study (Agin-Liebes et al., 2020) found 67% abstinence at 12 months. A Phase 2 RCT is ongoing.
• Alcohol use disorder. Two Phase 2 RCTs published in 2022 — one from NYU (Bogenschutz et al.) and one from the University of Zurich — found significant reductions in heavy drinking days following psilocybin-assisted therapy. MDMA-assisted therapy for alcohol use disorder also showed early promise in a Phase 2 trial (Sessa et al., 2021).
• Opioid dependence. Ibogaine has shown striking efficacy at interrupting opioid withdrawal and reducing subsequent use in observational studies, and a 2024 Stanford trial in veterans (Nature Medicine) found significant reductions in PTSD, depression, and disability alongside improvements in psychological wellbeing. Regulatory and cardiac safety barriers remain substantial. Psilocybin for opioid dependence is in early-phase investigation.
• Cocaine use disorder. Phase 2 trials of ibogaine and psilocybin for cocaine dependence are underway, with preliminary signals of benefit. This remains an early-stage area.

Across addiction studies, a consistent finding is that therapeutic outcomes correlate with the intensity of the psychedelic experience and with the quality of post-session integration — reinforcing the importance of the therapeutic model rather than the pharmacology alone.

End-of-Life Distress

Psilocybin and LSD-assisted therapy for existential distress in patients with life-threatening illness represents one of the most historically grounded and ethically compelling applications in the field. Research from the 1960s at Spring Grove and Maryland Psychiatric Research Center showed significant reductions in anxiety, pain, and distress in cancer patients. This work was revived in landmark trials at Johns Hopkins and NYU in the 2010s.

Griffiths and colleagues (2016) and Ross and colleagues (2016) both published randomised controlled trials finding that a single psilocybin session produced large, durable reductions in anxiety, depression, and death anxiety in patients with life-threatening cancer diagnoses. At 6-month follow-up, 60–80% of participants met criteria for clinically significant antidepressant or anxiolytic response. Critically, the magnitude of therapeutic effect correlated significantly with the intensity of mystical-type experience during the session. A long-term follow-up by Agin-Liebes et al. (2020) found these gains persisted in most participants at 4.5 years.

These findings have particular significance: they suggest that psilocybin can meaningfully address the existential and relational dimensions of suffering that standard palliative care often cannot reach.

Eating Disorders

Eating disorders — particularly anorexia nervosa — represent a condition with the highest mortality rate of any psychiatric diagnosis and severely limited treatment options. Psilocybin-assisted therapy is now in early-phase investigation, with preliminary findings attracting significant clinical interest.

Foldi and colleagues (2021) proposed a theoretical model for psilocybin in anorexia based on its capacity to disrupt rigid, self-referential cognitive patterns — precisely the psychological signature of severe restrictive eating. Peck and colleagues (2023) published the first open-label pilot of psilocybin for anorexia nervosa, finding it feasible, well-tolerated, and associated with reductions in eating disorder psychopathology at 1-month follow-up. Phase 2 trials are now underway at several centres. Psilocybin is also being investigated for binge eating disorder and bulimia nervosa, though these programmes are at earlier stages.

OCD and Related Conditions

Obsessive-compulsive disorder shares with depression a pattern of rigid, repetitive self-referential cognition that the DMN disruption model suggests psychedelics may specifically target. Moreno and colleagues (2006) published the first modern psilocybin trial for OCD at the University of Arizona, finding significant within-session reductions in symptoms across all doses tested — including a sub-psychedelic control dose — suggesting mechanisms beyond simple serotonergic stimulation.

A Phase 2 trial of psilocybin for OCD (Yale University) is ongoing. Early evidence also suggests potential for psilocybin in body dysmorphic disorder, a related condition characterised by intrusive and distressing preoccupation with perceived physical flaws. These applications remain in early-phase investigation.

Microdosing

Microdosing — taking sub-perceptual doses of psychedelics (typically 1/10 to 1/20 of a full dose) on a regular schedule — has attracted extraordinary popular interest. The scientific evidence is considerably more complicated than popular narratives suggest.

Observational and survey studies have reported improvements in mood, focus, creativity, and wellbeing among microdosers. However, controlled trials have produced more modest and inconsistent results. Szigeti and colleagues (2021), using a self-blinding citizen science design, found that participants who believed they were microdosing showed benefits regardless of whether they were actually receiving an active substance — suggesting substantial expectancy effects. Szigeti et al. (2023) replicated this pattern in a larger sample. Cavanna and colleagues (2022) found no significant cognitive or emotional benefit from LSD microdosing compared to placebo in a randomised, controlled crossover trial.

A 2023 pre-registered RCT at the University of Copenhagen (Jensen et al.) similarly found no significant benefit of psilocybin microdosing over placebo on primary cognitive and wellbeing outcomes. Taken together, the controlled trial literature suggests that many of the reported benefits of microdosing may be largely attributable to expectancy, rather than direct pharmacological action. This does not rule out benefits for some individuals or conditions, but the current evidence does not support the stronger claims circulating in popular culture.

The Role of Mystical Experience

One of the most consistent and theoretically significant findings in clinical psychedelic research is the correlation between the intensity of mystical-type experience (MTE) and positive therapeutic outcomes. Across multiple independent studies — depression, addiction, end-of-life anxiety — participants who report peak or complete mystical experiences during their sessions show substantially greater and more durable improvements than those who do not.

The Mystical Experience Questionnaire (MEQ), originally developed from the work of Walter Pahnke, operationalises MTE across dimensions including unity, noetic quality, sacredness, deeply felt positive mood, transcendence of time and space, and paradoxicality. Griffiths and colleagues have repeatedly demonstrated that MEQ scores predict therapeutic outcomes in psilocybin trials, even when controlling for other variables.

The mechanistic explanation remains contested. One interpretation is that mystical experiences produce lasting changes in self-concept and meaning-making that underlie mood and behaviour change. Another, consistent with the REBUS model, is that the depth of predictive hierarchy dissolution correlates with both experiential intensity and degree of therapeutic change. A third possibility is that expectancy effects are partially responsible — participants who have more powerful experiences may be more convinced of benefit. Disentangling these mechanisms is an active area of research.

Nature-Relatedness and Ecological Values

A consistent secondary finding across multiple studies is an increase in nature-relatedness following psychedelic experiences — an observation with significant implications given the context of ecological crisis.

Forstmann and Sagioglou (2017) found that lifetime psychedelic use predicted pro-environmental behaviour through increased nature-relatedness, controlling for personality and other substance use. Lyons and Carhart-Harris (2018) found similar patterns alongside decreased authoritarian political attitudes. Kettner and colleagues (2019) found significant increases in nature-relatedness following psychedelic experiences in a naturalistic ceremony context, persisting at 2-week, 4-week, and 2-year follow-up. More recently, Kettner and colleagues (2021) demonstrated in a pre-registered study that psychedelic experiences predicted increased nature-relatedness at 2-week and 4-week follow-up, with the effect mediated by ego dissolution during the experience.

These are correlational findings with significant methodological constraints — self-selection, expectancy effects, and the impossibility of adequate blinding all apply. But their convergence across independent samples, researchers, and study designs warrants serious theoretical attention.

Limits of the Evidence

The psychedelic research renaissance has produced genuinely significant findings. It has also attracted a degree of popular and institutional enthusiasm that sometimes outruns what the evidence can honestly support. Several structural limitations apply across much of the field:

• Functional unblinding. Truly double-blind trials are impossible: participants know whether they are having a psychedelic experience. This confounds outcomes in ways that are structurally unavoidable and methodologically unresolved. Measuring expectancy and attempting active placebos (e.g., niacin, low-dose psychedelics) are partial solutions, but none fully solves the problem.
• Small, homogeneous samples. Most published trials involve tens rather than hundreds of participants, recruited from populations that are typically educated, White, and psychedelically experienced. Generalisability to broader clinical populations — including those with complex trauma, concurrent substance use disorders, or limited therapeutic support — remains uncertain.
• Publication bias. The field's institutional excitement creates pressure toward positive reporting. Null results are underrepresented in the published literature. The COMPASS Phase 2b trial was a meaningful corrective, demonstrating that effect sizes in earlier open-label work were likely inflated.
• Integration and support as confounds. Psychedelic-assisted therapy packages a pharmacological intervention with intensive therapeutic contact — often 12–20 hours per treatment course. Disentangling pharmacological from psychotherapeutic effects is extremely difficult; the "drug effect" cannot be cleanly isolated.
• Long-term outcomes. Most trials assess outcomes at 1–6 months post-treatment. Very few have follow-up data beyond one year, making claims about durable efficacy difficult to evaluate rigorously.
• Equity and access. Current research predominantly serves populations with the resources and cultural capital to access highly structured, professionally supported psychedelic therapy. How these interventions scale, and what they look like in under-resourced settings, are critical and underaddressed questions.

None of these limitations invalidates the research — they contextualise it. The honest position is that psychedelic-assisted therapies show genuine and significant promise for multiple conditions where existing treatments are inadequate, while acknowledging that the evidence base is early, the methodological challenges are real, and the gap between laboratory findings and scalable clinical practice is substantial.